The Ka/Ks values of PtWRKY paralogous gene pairs. by Yuzhao Ma (12840632)

“…Under cadmium toxicity, <i><i>the plant</i></i> height of <i><i>PsnWRKY95</i></i>-overexpressing plants increased by 16%−26% compared with the wild type (WT), the root length increased by 12%−27% compared with WT, the peroxidase (POD) activity was 28%−51% higher than that of WT, the chlorophyll content increased by 15%−29% compared with WT, the malondialdehyde (MDA) content decreased by 13%−32% compared with WT, and the electrical conductivity decreased by 9%−20% compared with WT, with the expression levels of <i>POD</i> and <i>HMA1</i> in the overexpressing plants also being higher than those in WT. …”

RNA-seq data of WRKY genes. by Yuzhao Ma (12840632)

“…Under cadmium toxicity, <i><i>the plant</i></i> height of <i><i>PsnWRKY95</i></i>-overexpressing plants increased by 16%−26% compared with the wild type (WT), the root length increased by 12%−27% compared with WT, the peroxidase (POD) activity was 28%−51% higher than that of WT, the chlorophyll content increased by 15%−29% compared with WT, the malondialdehyde (MDA) content decreased by 13%−32% compared with WT, and the electrical conductivity decreased by 9%−20% compared with WT, with the expression levels of <i>POD</i> and <i>HMA1</i> in the overexpressing plants also being higher than those in WT. …”

Analysis of PtWRKY genes. by Yuzhao Ma (12840632)

“…Under cadmium toxicity, <i><i>the plant</i></i> height of <i><i>PsnWRKY95</i></i>-overexpressing plants increased by 16%−26% compared with the wild type (WT), the root length increased by 12%−27% compared with WT, the peroxidase (POD) activity was 28%−51% higher than that of WT, the chlorophyll content increased by 15%−29% compared with WT, the malondialdehyde (MDA) content decreased by 13%−32% compared with WT, and the electrical conductivity decreased by 9%−20% compared with WT, with the expression levels of <i>POD</i> and <i>HMA1</i> in the overexpressing plants also being higher than those in WT. …”

The primer sequences for RT-qPCR. by Yuzhao Ma (12840632)

“…Under cadmium toxicity, <i><i>the plant</i></i> height of <i><i>PsnWRKY95</i></i>-overexpressing plants increased by 16%−26% compared with the wild type (WT), the root length increased by 12%−27% compared with WT, the peroxidase (POD) activity was 28%−51% higher than that of WT, the chlorophyll content increased by 15%−29% compared with WT, the malondialdehyde (MDA) content decreased by 13%−32% compared with WT, and the electrical conductivity decreased by 9%−20% compared with WT, with the expression levels of <i>POD</i> and <i>HMA1</i> in the overexpressing plants also being higher than those in WT. …”

Prevalence of osteoporosis classified by sex, and urinary cadmium level compare between 2019 and 2022. by Aroon La-up (14095691)

Subjects:

<i>PsnWRKY95</i> transgenic plants selection and functional analysis of <i>PsnWRKY95</i> in cadmium resistance. by Yuzhao Ma (12840632)

Analysis of <i>PtWRKYs</i> expression in response to Cd. by Yuzhao Ma (12840632)

Map with color coding showing the relative risk of loss at the regional level for each country in Sub-Saharan Africa. by Beatrice T. Nganso (4114768)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects: